ClinicalTrials.gg
TerminatedNCT04070157TAPERUpdated Oct 21, 2024Results posted

Randomized, Double-Blind, Placebo-Controlled Pilot Study on the Safety and Effectiveness of LUCEMYRA During an Opioid Taper in Treatment of Withdrawal

A Phase 2 interventional study of Lofexidine and Placebo in Opioid Withdrawal (Disorder), sponsored by USWM, LLC (dba US WorldMeds). Terminated at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-21.

Sponsored by USWM, LLC (dba US WorldMeds) · Phase 2, Interventional, and Treatment

Why this study was terminated
COVID pandemic and enrollment issues necessitating an adjustment to the study design.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
4
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Stopping prescription opioid pain medications can be difficult due to withdrawal symptoms. This study will test if LUCEMYRA helps reduce withdrawal symptoms and helps more people reduce their opioid dose compared to placebo.

Read the detailed description

This randomized, double-blind, placebo-controlled pilot study will evaluate the safety and effectiveness of LUCEMYRA in the treatment of opioid withdrawal during an opioid taper in subjects with chronic non-cancer pain.

Subjects will begin a planned 14-day complete taper of their pre-study opioid medications and will be randomly assigned (1:1) to either LUCEMYRA or matching placebo. Study drug will be administered through the opioid taper and for 5 days after the opioid taper is completed. Study drug will then be tapered over a 4-day period for a total of approximately 21 days exposure to study drug.

02

Conditions studied

  • Opioid Withdrawal (Disorder)

Keywords

  • Opioid Withdrawal Syndrome
  • OWS
  • Opioid taper
  • Opioid withdrawal
  • Opioid reduction
  • Stopping opioids
  • Opioid discontinuation
  • non-opioid pain management
03

In context

Lead sponsor

USWM, LLC (dba US WorldMeds) is the lead sponsor of 17 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject can provide written .
  • Chronic non-cancer pain diagnosis such as low back pain, chronic neck pain, osteoarthritis, and prolonged post-surgical pain with daily pain for a minimum of 6 months.
  • Self-reported use of prescribed oral opioid medication(s) (tablets, pills or capsules) of at least 50 morphine mg equivalent (MME) but no higher than 240 mg MME daily or near daily (≥5 days per week) for at least 12 weeks and seeking to discontinue their opioid medication.
  • Willing to be treated with non-opioid treatments for pain (in addition to opioid being tapered) for duration of study.
  • Willing to abstain from alcohol use during the study.
  • Willing to partner with his or her pain physician on a subject-centered pain management plan during the study.
  • In generally good health, in the opinion of the Investigator, other than the underlying chronic pain syndrome
  • Women of must have a negative pregnancy test at Screening.
  • Non-pregnant, non-lactating women who are , naturally or surgically sterile, or who agree to use acceptable methods throughout the course of the study.
  • Other criteria will be discussed in detail with potential subjects by Site Investigator

Exclusion criteria

Exclusion Criteria:

  • Has a primary diagnosis of complex regional pain syndrome, central neuropathic pain, somatoform pain syndromes, acute nerve root compression, any acute or progressive infectious, inflammatory, or neurological process.
  • Taking methadone, buprenorphine, fentanyl rapid acting products, tapentadol, tramadol, butorphanol, meperidine, or levorphanol for any reason
  • Liver disease that requires medication or medical treatment, and/or or ALT levels greater than 3 x .
  • Gastrointestinal or renal disease, which would significantly impair absorption, metabolism or excretion of study drug, or would require medication or medical treatment.
  • Has a diagnosis of epilepsy or history of seizures.
  • Cardiovascular abnormalities at Screening and before randomization (stable hypertension permitted)
  • Self-reported or evidence of opioid use disorder (OUD) or other substance use disorder within last 12 months
  • Any severe or unstable psychiatric disorder including post-traumatic stress disorder, schizophrenia, bipolar disorder, major depression, substance abuse, or suicidality as determined by the Investigator.
  • Subject answers "yes" to "suicidal ideation" in prior 24 months to any items 1 through 5 on the C-SSRS, or subject answers "yes" to any lifetime "suicidal behavior" item on the C-SSRS.
  • Any anticipated or scheduled surgery during the study period or within 30 days before Screening.
  • Other criteria will be discussed in detail with potential subjects by site Investigator
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    Lofexidine

    Drug: Lofexidine

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Lofexidine 0.18 mg tablets. Dosing will begin with 1 tablet administered every 5-6 hours, up to 4 times day. The dose may be titrated but not to exceed 4 tablets 4 times a day.

    Also known as: lofexidine hydrochloride, LUCEMYRA

  • DrugPlacebo

    Matching placebo tablets. Dosing will begin with 1 tablet administered every 5-6 hours, up to 4 times day. The dose may be titrated but not to exceed 4 tablets 4 times a day.

06

What researchers measure

Primary outcomes

  1. Number of Treatment Emergent AEs and SAEs

    Time frame: Day 1 through Day 28

  2. Number and Percent of Subjects Reporting TEAEs Resulting in Study Drug Discontinuation

    Time frame: Day 1 through Day 28

  3. Percentage of Subjects With Treatment-emergent Elevated Liver Function Tests

    Time frame: Day 1 through Day 28

  4. Percentage of Subjects Identified as Suicide Risk With Columbia Suicide Severity Rating Scale

    The C-SSRS measures both suicidal ideation and suicidal behavior. The Screener contains "yes" or "no" questions in which respondents are asked to indicate whether they have experienced several thoughts or feelings relating to suicide. A significant risk of suicide is defined as a "yes" in answer to: a) questions 4 or 5 on the suicidal ideation section, or b) any questions on any item in the suicidal behavior section. This must be reported as an SAE and followed up accordingly. Additionally, if a subject responds "yes" to any of the suicidal ideation questions 1 to 3, the Investigator should apply clinical judgment to determine the need for reporting as an AE or SAE and the need for any referral.

    Time frame: Day 1 through Day 28

  5. Change in Blood Pressure

    Orthostatic vital signs were measured in-clinic only. When the subject is at home, only resting vital signs will be collected. Orthostatic vital signs will be measured first after the subject has been sitting for at least 5 minutes and then after the subject has been standing for at least 3 minutes. Resting vital signs only will be measured at home and will be measured after the subject has been sitting quietly for at least 5 minutes.

    Time frame: Baseline to Days 1, 2, 3, 7, 8, 14, 15, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27 and 28

  6. Change in Pulse

    Time frame: Baseline to Days 1, 2, 3, 7, 8, 14, 15, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27 and 28

Secondary outcomes

  1. Percentage of Subjects Who Successfully Complete Each Scheduled Dose Reduction and the Opioid Taper to Complete Opioid Discontinuation

    Time frame: Day 1 through Day 28

  2. Change in Clinical Opiate Withdrawal Scale (COWS)

    The COWS is a clinician-administered instrument that rates 11 common opioid withdrawal signs and symptoms. These include: resting pulse rate; sweating; restlessness; pupil size; bone or joint aches; runny nose or tearing; gastrointestinal upset; tremor; yawning; anxiety or irritability; and gooseflesh skin. Lower total scores indicate a more positive clinical outcome. Score: 5-12 = mild; 13-24 = moderately severe; more than 36 = severe withdrawal. Scores range from a minimum of 0 to a maximum of 48.

    Time frame: Day 1 (pre-1st dose) to Days 3, 8, 15, 22 and 28

  3. Change in the Short Opiate Withdrawal Scale of Gossop (SOWS-G)

    The SOWS-Gossop scale assesses subjective symptoms of opioid withdrawal. It is a subject-rated scale consisting of 10 items that are scored on a 4-point scale of 0 = none, 1 = mild, 2 = moderate, and 3 = severe (minimum score of 0, maximum score of 30). The overall score is the simple sum of the 10 item scores. Lower observed values in SOWS-Gossop scores indicate a more positive clinical outcome.

    Time frame: Day 1 (pre-1st dose) to Days 1 (at bedtime), 2, 3, 4, 5, 6, 7, 8, 9, 10,11, 12,13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27 and 28

  4. Change in Subjective Opiate WIthdrawal Scale of Handelsman (SOWS-H)

    The SOWS-H scale assesses subjective symptoms of opioid withdrawal. It is a subject-rated scale consisting of 19 items that are scored on a 5-point scale of 0 = not at all, 1 = a little, 2 = moderately, 3 = quite a bit, and 4 = extremely. The overall score is the simple sum of the 19 item scores. Lower observed values in SOWS-H scores indicate a more positive clinical outcome.

    Time frame: Day 1 (pre-1st dose) to Days 1 (at bedtime), 2, 3, 4, 5, 6, 7, 8, 9, 10,11, 12,13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27 and 28

  5. Modified Clinical Global Impression - Rater Version (MCGI-R) Average Score

    MCGI-R includes 2 items: A 7-point scale that allows clinicians to rate the severity of a subject's opiate withdrawal symptoms. A 4-point scale that allows clinicians to rate the degree of a subject's side effects from study drug. SEVERITY OF ILLNESS: 1. = No at all ill 2. = Borderline ill 3. = Mildly ill 4. = Moderately ill 5. = Markedly ill 6. = Severely ill 7. = Among the most extremely ill subjects SIDE EFFECTS INDEX: 1. = None, study drug is producing no side effects 2. = Do not significantly interfere with subject's functioning 3. = Significantly interferes with subject's functioning 4. = Outweighs therapeutic effect

    Time frame: Each scheduled evaluation (Study Visits 2, 3, 4, 5, EOS)

  6. Modified Clinical Global Impression - Subject Version (MCGI-S)

    Includes: A 7-point scale for subjects to rate the severity of opiate withdrawal symptoms. A 4-point scale for subjects to rate the degree of side effects from their study drug. SEVERITY OF OPIATE WITHDRAWAL: 1. = No opiate withdrawal symptoms 2. = On the border between no to mild opiate withdrawal symptoms 3. = Mild opiate withdrawal symptoms 4. = Moderate opiate withdrawal symptoms 5. = Marked opiate withdrawal symptoms 6. = Severe opiate withdrawal symptoms 7. = The most severe opiate withdrawal symptoms that I have ever had SIDE EFFECTS INDEX (Scale B): 1. = None. The study drug has no side effects 2. = The study drug has slight side effects, but it does NOT significantly interfere with my day to day activities 3. = The study drug has moderate side effects, and it DOES significantly interfere with my day to day activities 4. = The study drug has severe side effects, and these side effects are greater than the relief from opiate withdrawal symptoms that it provides

    Time frame: Each scheduled evaluation (Day 1 through Day 28)

  7. Time to Study Drug Discontinuation

    Study day of participant discontinuation.

    Time frame: Day 1 through Day 28

  8. Number of Non-opioid Concomitant Medications for Withdrawal Symptoms Used by Study Day

    Time frame: Day 1 through Day 28

  9. Change in EuroQol 5-Dimension 5-Level (EQ-5D-5L) Scale

    The EQ-5D-5L is an instrument that evaluates preference for health status through 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each of which are rated on 5 levels of severity. Each dimension ranges from a minimum of "0 - I have no problems or I am not" to a maximum of "5 - I am unable to or I am extremely". The dimensions are averaged together for a single score and the change in average score from baseline is recorded.

    Time frame: Change from Baseline to EOS

  10. Change in Short Form Health Survey (SF-36) Scale

    The SF-36 consists of 36 questions that measure various aspects of physical and mental well-being. Precoded values are recorded for each question ranging from 0-100, with a high score defined as a more favorable health status. The items are then averaged together to create the 8 scale scores which are averaged together to create a scale. The final value reported is the average change in the averaged scale scores from baseline to end of study.

    Time frame: Change from baseline to End of Study, up to 55 days

  11. Change in Insomnia Severity Index (ISI)

    The ISI is a 7-item self-report questionnaire assessing the nature, severity, and impact of insomnia. The dimensions evaluated are: severity of sleep onset, sleep maintenance and early morning awakening problems, sleep dissatisfaction, interference of sleep difficulties with daytime functioning, noticeability of sleep problems by others, and distress caused by the sleep difficulties. A 5-point Likert scale is used to rate each item on a scale 0 to 4 for each of the 7 items, yielding a total score ranging from 0 to 28. The total score is interpreted as follows: absence of insomnia (0-7); sub-threshold insomnia (8-14); moderate insomnia (15-21); and severe insomnia (22-28).

    Time frame: Change from baseline to Days 15 and End of Study, up to 55 days

  12. Change in Hospital Anxiety and Depression Scale (HADS)

    The HADS is a self-reported screening tool for anxiety and depression in nonpsychiatric clinical populations. Responses are based on the relative frequency of symptoms over the preceding week. The scale consists of 14 items, with a subscale of 7 questions for anxiety and 7 questions for depression. Patients rate each item in the subscales on a 4-point scale ranging from 0 (absence) to 3 (extreme presence). Possible scores range from 0 to 21 for each subscale. An analysis of scores on the 2 subscales supported the differentiation of each mood state into 4 ranges: non-cases (scores 0 to 7), mild cases (scores 8 to 10), moderate cases (scores 11 to 15), and severe cases (scores 16 or higher), with lower values being favorable. The subscales are then combined for a total score ranging from 0 to 42. Higher scores indicate greater levels of anxiety or depression. The value reported is the average change from baseline to End of Study.

    Time frame: Change from End of Study to Baseline, up to 55 days

  13. Change in Average Chronic Pain as Measured by the Numeric Rating Scale (NRS)

    A subject selects a whole number (0 to 10) that best indicates the intensity of his/her pain. The format consists of a horizontal line which is anchored by terms defining pain levels where 0 represents no pain and 10 represents worst pain imaginable.

    Time frame: Baseline through Follow-up (assessed daily)

  14. Change in Average Overall Pain as Measured by the Numeric Rating Scale (NRS)

    The NRS of pain intensity is a unidimensional, segmented numeric version of the visual analog scale. A subject selects a whole number (0 to 10) that best indicates the intensity of his/her pain. The format consists of a horizontal line which is anchored by terms defining pain levels where 0 represents no pain and 10 represents worst pain imaginable.

    Time frame: Day 1 through Day 28 (assessed daily)

  15. Change in Worst Chronic Pain as Measured by the Numeric Rating Scale (NRS)

    The NRS of pain intensity is a unidimensional, segmented numeric version of the visual analog scale. A subject selects a whole number (0 to 10) that best indicates the intensity of his/her pain. The format consists of a horizontal line which is anchored by terms defining pain levels where 0 represents no pain and 10 represents worst pain imaginable.

    Time frame: Baseline through Day 51 (assessed daily)

  16. Change in Worst Overall Pain as Measured by the Numeric Rating Scale (NRS)

    The NRS of pain intensity is a unidimensional, segmented numeric version of the visual analog scale. A subject selects a whole number (0 to 10) that best indicates the intensity of his/her pain. The format consists of a horizontal line which is anchored by terms defining pain levels where 0 represents no pain and 10 represents worst pain imaginable.

    Time frame: Day 1 through Day 28 (assessed daily)

  17. Change in Daily Opioid Dose Expressed as Morphine Equivalent Dose (MED)

    Time frame: Baseline through Day 28

  18. Change in Daily Opioid Dose as a Percentage of the Baseline MED

    Time frame: Baseline through Day 28

07

Results

Posted Oct 21, 2024

Participant flow

Participant flow — Overall Study
MilestoneLofexidinePlacebo
Started13
Completed02
Not completed11

Outcome measures

PrimaryNumber of Treatment Emergent AEs and SAEs
Time frame:
Day 1 through Day 28
Reported as:
Number · participants
Number of Treatment Emergent AEs and SAEs
participantsLofexidinePlacebo
Adverse Events05
Serious Adverse Events00
PrimaryNumber and Percent of Subjects Reporting TEAEs Resulting in Study Drug Discontinuation
Time frame:
Day 1 through Day 28
Reported as:
Count of participants · Participants
Number and Percent of Subjects Reporting TEAEs Resulting in Study Drug Discontinuation
ParticipantsLofexidinePlacebo
Number and Percent of Subjects Reporting TEAEs Resulting in Study Drug Discontinuation01
PrimaryPercentage of Subjects With Treatment-emergent Elevated Liver Function Tests
Time frame:
Day 1 through Day 28
Reported as:
Count of participants · Participants
Percentage of Subjects With Treatment-emergent Elevated Liver Function Tests
ParticipantsLofexidinePlacebo
Percentage of Subjects With Treatment-emergent Elevated Liver Function Tests00
PrimaryPercentage of Subjects Identified as Suicide Risk With Columbia Suicide Severity Rating Scale

The C-SSRS measures both suicidal ideation and suicidal behavior. The Screener contains "yes" or "no" questions in which respondents are asked to indicate whether they have experienced several thoughts or feelings relating to suicide. A significant risk of suicide is defined as a "yes" in answer to: a) questions 4 or 5 on the suicidal ideation section, or b) any questions on any item in the suicidal behavior section. This must be reported as an SAE and followed up accordingly. Additionally, if a subject responds "yes" to any of the suicidal ideation questions 1 to 3, the Investigator should apply clinical judgment to determine the need for reporting as an AE or SAE and the need for any referral.

Time frame:
Day 1 through Day 28
Reported as:
Number · % of subjects with suicide risk
Percentage of Subjects Identified as Suicide Risk With Columbia Suicide Severity Rating Scale
% of subjects with suicide riskLofexidinePlacebo
Percentage of Subjects Identified as Suicide Risk With Columbia Suicide Severity Rating Scale00
PrimaryChange in Blood Pressure

Orthostatic vital signs were measured in-clinic only. When the subject is at home, only resting vital signs will be collected. Orthostatic vital signs will be measured first after the subject has been sitting for at least 5 minutes and then after the subject has been standing for at least 3 minutes. Resting vital signs only will be measured at home and will be measured after the subject has been sitting quietly for at least 5 minutes.

Time frame:
Baseline to Days 1, 2, 3, 7, 8, 14, 15, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27 and 28
Reported as:
Mean · mmHg
Change in Blood Pressure
mmHgLofexidine: SittingLofexidine: StandingPlacebo: SittingPlacebo: Standing
Day 1: Diastolic BP-2 ± NA0 ± NA-0.3 ± 3.06-0.7 ± 3.21
Day 1: Systolic BP-6 ± NA0 ± NA1.7 ± 2.31-0.3 ± 1.53
Day 2: Diastolic BP-7 ± NA—3 ± 5.66—
Day 2: Systolic BP-25 ± NA—7 ± 9.9—
Day 3: Diastolic BP-16 ± NA-9 ± NA1.5 ± 3.875 ± 6
Day 3: Systolic BP-52 ± NA-44 ± NA6.5 ± 7.726 ± 7.94
Day 7: Diastolic BP-16 ± NA—7 ± 8.72—
Day 7: Systolic BP-50 ± NA—6 ± 7—
Day 8: Diastolic BP-10 ± NA-8 ± NA3.3 ± 9.455.3 ± 5.86
Day 8: Systolic BP-44 ± NA-36 ± NA4 ± 113 ± 11
Day 14: Diastolic BP-8 ± NA—1.7 ± 10.5—
Day 14: Systolic BP-42 ± NA—4.7 ± 10.02—
Day 15: Diastolic BP-10 ± NA-4 ± NA1 ± 7.813.3 ± 7.77
Day 15: Systolic BP-32 ± NA-40 ± NA10.7 ± 16.074.3 ± 13.01
Day 18: Diastolic BP——10.7 ± 6.35—
Day 18: Systolic BP——14.3 ± 0.58—
Day 19: Diastolic BP——6.3 ± 4.5—
Day 19: Systolic BP——11 ± 6.22—
Day 20: Diastolic BP——1.8 ± 5.91—
Day 20: Systolic BP——4.3 ± 7.68—
Day 21: Diastolic BP——8.5 ± 3.42—
Day 21: Systolic BP——11.8 ± 11.12—
Day 22: Diastolic BP-16 ± NA-8 ± NA4.3 ± 3.7210 ± 1.41
Day 22: Systolic BP-25 ± NA-34 ± NA9.7 ± 16.0216 ± 1.41
Day 23: Diastolic BP-3.5 ± NA—3.5 ± 5.45—
Day 23: Systolic BP-19 ± NA—11.5 ± 12.23—
Day 24: Diastolic BP-1.5 ± NA—6.3 ± 4.5—
Day 24: Systolic BP-23.5 ± NA—9.5 ± 6.61—
Day 25: Diastolic BP——4.7 ± 3.56—
Day 25: Systolic BP——8.5 ± 9.57—
Day 26: Diastolic BP1.5 ± NA—9.3 ± 7.46—
Day 26: Systolic BP-14 ± NA—8.5 ± 19.28—
Day 27: Diastolic BP——4.8 ± 4.67—
Day 27: Systolic BP——7.7 ± 8.16—
Day 28: Diastolic BP——11 ± 7.077.5 ± 4.95
Day 28: Systolic BP——22 ± 7.0715.5 ± 14.85
Day 29: Diastolic BP——-0.5 ± NA—
Day 29: Systolic BP——18 ± NA—
Day 30: Diastolic BP——-1.5 ± NA—
Day 30: Systolic BP——8 ± NA—
Day 34: Diastolic BP——0.5 ± NA—
Day 34: Systolic BP——12.5 ± NA—
Day 37: Diastolic BP——0 ± NA3 ± NA
Day 37: Systolic BP——-5 ± NA-5 ± NA
PrimaryChange in Pulse
Time frame:
Baseline to Days 1, 2, 3, 7, 8, 14, 15, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27 and 28
Reported as:
Mean · bpm
Change in Pulse
bpmLofexidine: SittingLofexidine: StandingPlacebo: SittingPlacebo: Standing
Day 11 ± NA0 ± NA-5 ± 2.65-0.3 ± 3.21
Day 2-2 ± NA—-9 ± 4.24—
Day 3-4 ± NA-5 ± NA-7.3 ± 2.63-5.3 ± 0.58
Day 70 ± NA—-2 ± 9.54—
Day 8-2 ± NA-4 ± NA-1 ± 3.46-0.7 ± 0.58
Day 14-1 ± NA—-1.7 ± 7.09—
Day 15-2 ± NA0 ± NA-11 ± 8.19-3 ± 3.46
Day 18——1.7 ± 2.89—
Day 19——-2.8 ± 4.03—
Day 20——-8.8 ± 5.12—
Day 21——-1.8 ± 8.54—
Day 22-4 ± NA-5 ± NA-6 ± 4.1-7 ± 2.83
Day 230.5 ± NA—-4 ± 11.8—
Day 24-1 ± NA—-6.5 ± 4.2—
Day 25——-0.8 ± 7.78—
Day 260.5 ± NA—-9 ± 4.97—
Day 27——-5.5 ± 7.31—
Day 28——-7.5 ± 3.54-7 ± 11.31
Day 29——3.5 ± NA—
Day 30——1.5 ± NA—
Day 34——2.5 ± NA—
Day 37——-13 ± NA-8 ± NA
SecondaryPercentage of Subjects Who Successfully Complete Each Scheduled Dose Reduction and the Opioid Taper to Complete Opioid Discontinuation
Time frame:
Day 1 through Day 28
Reported as:
Count of participants · Participants
Percentage of Subjects Who Successfully Complete Each Scheduled Dose Reduction and the Opioid Taper to Complete Opioid Discontinuation
ParticipantsLofexidinePlacebo
Percentage of Subjects Who Successfully Complete Each Scheduled Dose Reduction and the Opioid Taper to Complete Opioid Discontinuation02
SecondaryChange in Clinical Opiate Withdrawal Scale (COWS)

The COWS is a clinician-administered instrument that rates 11 common opioid withdrawal signs and symptoms. These include: resting pulse rate; sweating; restlessness; pupil size; bone or joint aches; runny nose or tearing; gastrointestinal upset; tremor; yawning; anxiety or irritability; and gooseflesh skin. Lower total scores indicate a more positive clinical outcome. Score: 5-12 = mild; 13-24 = moderately severe; more than 36 = severe withdrawal. Scores range from a minimum of 0 to a maximum of 48.

Time frame:
Day 1 (pre-1st dose) to Days 3, 8, 15, 22 and 28
Reported as:
Mean · score on a scale
Change in Clinical Opiate Withdrawal Scale (COWS)
score on a scaleLofexidinePlacebo
Day 32-0.7 ± 0.58
Day 83-1 ± 2
Day 154-1.3 ± 0.58
Day 22-1-2.5 ± 0.71
End of Study-1-2.3 ± 0.58
SecondaryChange in the Short Opiate Withdrawal Scale of Gossop (SOWS-G)

The SOWS-Gossop scale assesses subjective symptoms of opioid withdrawal. It is a subject-rated scale consisting of 10 items that are scored on a 4-point scale of 0 = none, 1 = mild, 2 = moderate, and 3 = severe (minimum score of 0, maximum score of 30). The overall score is the simple sum of the 10 item scores. Lower observed values in SOWS-Gossop scores indicate a more positive clinical outcome.

Time frame:
Day 1 (pre-1st dose) to Days 1 (at bedtime), 2, 3, 4, 5, 6, 7, 8, 9, 10,11, 12,13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27 and 28
Reported as:
Mean · score on a scale
Change in the Short Opiate Withdrawal Scale of Gossop (SOWS-G)
score on a scaleLofexidinePlacebo
Day 21 ± NA-0.5 ± 3
Day 31 ± NA-2.2 ± 3.56
Day 4—-0.7 ± 5.03
Day 51 ± NA-0.3 ± 5.51
Day 6—0.3 ± 5.03
Day 71 ± NA-2.5 ± 3.54
Day 81.5 ± NA-1.4 ± 4.72
Day 9—2 ± 6
Day 104 ± NA-4.5 ± 0.71
Day 11—-0.3 ± 6.35
Day 122 ± NA-4.5 ± 0.71
Day 134 ± NA-1 ± 6.08
Day 145 ± NA-1 ± 6.08
Day 152.7 ± NA-4.3 ± 0.96
Day 16—1.5 ± 6.45
Day 17—-4 ± 1.41
Day 18—-4 ± 1.41
Day 19—-4 ± 1.41
Day 20—-4 ± 1.41
Day 21—-4 ± 1.41
Day 22—-3.8 ± 2.49
Day 23—-2.7 ± 2.52
Day 24-1 ± NA-3 ± 3
Day 25-1 ± NA-4.5 ± 2.12
Day 26—-3 ± 3
Day 271 ± NA-4 ± 1.41
Day 28—-3.8 ± 2.87
SecondaryChange in Subjective Opiate WIthdrawal Scale of Handelsman (SOWS-H)

The SOWS-H scale assesses subjective symptoms of opioid withdrawal. It is a subject-rated scale consisting of 19 items that are scored on a 5-point scale of 0 = not at all, 1 = a little, 2 = moderately, 3 = quite a bit, and 4 = extremely. The overall score is the simple sum of the 19 item scores. Lower observed values in SOWS-H scores indicate a more positive clinical outcome.

Time frame:
Day 1 (pre-1st dose) to Days 1 (at bedtime), 2, 3, 4, 5, 6, 7, 8, 9, 10,11, 12,13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27 and 28
Reported as:
Mean · score on a scale
Change in Subjective Opiate WIthdrawal Scale of Handelsman (SOWS-H)
score on a scaleLofexidinePlacebo
Day 2-4 ± NA0.3 ± 3.77
Day 3-5 ± NA-1 ± 4.3
Day 4—2.3 ± 5.51
Day 5-3 ± NA3 ± 6.24
Day 6—3.3 ± 8.02
Day 7-4 ± NA0 ± 5.66
Day 8-2.5 ± NA1.8 ± 6.3
Day 9—3.5 ± 7.59
Day 100 ± NA-1.5 ± 3.54
Day 11—0.7 ± 6.35
Day 12-3 ± NA-4 ± 0
Day 132 ± NA-0.3 ± 8.14
Day 141 ± NA0.7 ± 8.96
Day 150.7 ± NA-3.5 ± 1.29
Day 16—4.3 ± 9
Day 17—-4 ± 1.41
Day 18—-3 ± 0
Day 19—-3 ± 0
Day 20—-3.5 ± 0.71
Day 21—-4 ± 0
Day 22—-2.8 ± 1.3
Day 23—-3.3 ± 2.08
Day 24-5 ± NA-2.3 ± 2.89
Day 25-5 ± NA-4.5 ± 0.71
Day 26—-3.3 ± 2.52
Day 27-6 ± NA-4 ± 0
Day 28-3 ± NA-3.8 ± 1.89
SecondaryModified Clinical Global Impression - Rater Version (MCGI-R) Average Score

MCGI-R includes 2 items: A 7-point scale that allows clinicians to rate the severity of a subject's opiate withdrawal symptoms. A 4-point scale that allows clinicians to rate the degree of a subject's side effects from study drug. SEVERITY OF ILLNESS: 1. = No at all ill 2. = Borderline ill 3. = Mildly ill 4. = Moderately ill 5. = Markedly ill 6. = Severely ill 7. = Among the most extremely ill subjects SIDE EFFECTS INDEX: 1. = None, study drug is producing no side effects 2. = Do not significantly interfere with subject's functioning 3. = Significantly interferes with subject's functioning 4. = Outweighs therapeutic effect

Time frame:
Each scheduled evaluation (Study Visits 2, 3, 4, 5, EOS)
Reported as:
Mean · score on a scale
Modified Clinical Global Impression - Rater Version (MCGI-R) Average Score
score on a scaleLofexidine Severity of Illness Scale Averages:Placebo Severity of Illness Scale Averages:Lofexidine Side Effects Index Averages:Placebo Side Effects Index Averages:
Visit 21 ± NA1 ± NA1 ± NA1 ± NA
Visit 31 ± NA1.33 ± 0.4711 ± NA1.33 ± 0.471
Visit 41 ± NA1 ± NA1 ± NA1 ± NA
Visit 51 ± NA1 ± NA1 ± NA1 ± NA
EOS1 ± NA1 ± NA1 ± NA1 ± NA
SecondaryModified Clinical Global Impression - Subject Version (MCGI-S)

Includes: A 7-point scale for subjects to rate the severity of opiate withdrawal symptoms. A 4-point scale for subjects to rate the degree of side effects from their study drug. SEVERITY OF OPIATE WITHDRAWAL: 1. = No opiate withdrawal symptoms 2. = On the border between no to mild opiate withdrawal symptoms 3. = Mild opiate withdrawal symptoms 4. = Moderate opiate withdrawal symptoms 5. = Marked opiate withdrawal symptoms 6. = Severe opiate withdrawal symptoms 7. = The most severe opiate withdrawal symptoms that I have ever had SIDE EFFECTS INDEX (Scale B): 1. = None. The study drug has no side effects 2. = The study drug has slight side effects, but it does NOT significantly interfere with my day to day activities 3. = The study drug has moderate side effects, and it DOES significantly interfere with my day to day activities 4. = The study drug has severe side effects, and these side effects are greater than the relief from opiate withdrawal symptoms that it provides

Time frame:
Each scheduled evaluation (Day 1 through Day 28)
Reported as:
Mean · score on a scale
Modified Clinical Global Impression - Subject Version (MCGI-S)
score on a scaleLofexidine Severity of Opiate Withdrawal Averages:Placebo Severity of Opiate Withdrawal Averages:Lofexidine Side Effects Index Averages:Placebo Side Effects Index Averages:
Day 211.33 ± 0.47111 ± NA
Day 311 ± NA11 ± NA
Day 4—2 ± NA—2 ± NA
Day 511.66 ± 0.47111.66 ± 0.471
Day 6—2 ± NA—1.66 ± 0.471
Day 711.66 ± 0.47111.66 ± 0.471
Day 812 ± NA12 ± NA
Day 9—1.66 ± 0.471—1.66 ± 0.471
Day 1012 ± NA11.66 ± 0.471
Day 11—1.66 ± 0.471—1.66 ± 0.471
Day 1212 ± NA12 ± NA
Day 1311.66 ± 0.47111.66 ± 0.471
Day 1412 ± NA11.66 ± 0.471
Day 1511.66 ± 0.47111.66 ± 0.471
Day 16—2 ± NA—1.66 ± 0.471
Day 17—1.5 ± 0.5—1.5 ± 0.5
Day 18—1.5 ± 0.5—2 ± NA
Day 19—1.5 ± 0.5—2 ± NA
Day 20—1.5 ± 0.5—2 ± NA
Day 21—1.5 ± 0.5—2 ± NA
Day 22—1.33 ± 0.471—1.66 ± 0.471
Day 23—1 ± NA—1 ± NA
Day 2411.33 ± 0.47111 ± NA
Day 2511.5 ± 0.511 ± NA
Day 26—1.33 ± 0.471—1 ± NA
Day 2711.5 ± 0.511 ± NA
Day 28—1.33 ± 0.47111 ± NA
SecondaryTime to Study Drug Discontinuation

Study day of participant discontinuation.

Time frame:
Day 1 through Day 28
Reported as:
Number · Days to study discontinuation
Time to Study Drug Discontinuation
Days to study discontinuationLofexidinePlacebo: Patient 1Placebo: Patient 2Placebo: Patient 3
Time to Study Drug Discontinuation21202224
SecondaryNumber of Non-opioid Concomitant Medications for Withdrawal Symptoms Used by Study Day
Time frame:
Day 1 through Day 28
Reported as:
Number · Number concomitant medication
Number of Non-opioid Concomitant Medications for Withdrawal Symptoms Used by Study Day
Number concomitant medicationLofexidinePlacebo: Patient 1Placebo: Patient 2Placebo: Patient 3
Day 1-15:0111
Day 16- Day 28:111—
SecondaryChange in EuroQol 5-Dimension 5-Level (EQ-5D-5L) Scale

The EQ-5D-5L is an instrument that evaluates preference for health status through 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each of which are rated on 5 levels of severity. Each dimension ranges from a minimum of "0 - I have no problems or I am not" to a maximum of "5 - I am unable to or I am extremely". The dimensions are averaged together for a single score and the change in average score from baseline is recorded.

Time frame:
Change from Baseline to EOS
Reported as:
Mean · score on a scale
Change in EuroQol 5-Dimension 5-Level (EQ-5D-5L) Scale
score on a scaleLofexidinePlacebo
Change in EuroQol 5-Dimension 5-Level (EQ-5D-5L) Scale-0.40 ± NA-0.13 ± 0.462
SecondaryChange in Short Form Health Survey (SF-36) Scale

The SF-36 consists of 36 questions that measure various aspects of physical and mental well-being. Precoded values are recorded for each question ranging from 0-100, with a high score defined as a more favorable health status. The items are then averaged together to create the 8 scale scores which are averaged together to create a scale. The final value reported is the average change in the averaged scale scores from baseline to end of study.

Time frame:
Change from baseline to End of Study, up to 55 days
Reported as:
Mean · score on a scale
Change in Short Form Health Survey (SF-36) Scale
score on a scaleLofexidinePlacebo
Change in Short Form Health Survey (SF-36) Scale-5 ± NA-1.7 ± 2.52
SecondaryChange in Insomnia Severity Index (ISI)

The ISI is a 7-item self-report questionnaire assessing the nature, severity, and impact of insomnia. The dimensions evaluated are: severity of sleep onset, sleep maintenance and early morning awakening problems, sleep dissatisfaction, interference of sleep difficulties with daytime functioning, noticeability of sleep problems by others, and distress caused by the sleep difficulties. A 5-point Likert scale is used to rate each item on a scale 0 to 4 for each of the 7 items, yielding a total score ranging from 0 to 28. The total score is interpreted as follows: absence of insomnia (0-7); sub-threshold insomnia (8-14); moderate insomnia (15-21); and severe insomnia (22-28).

Time frame:
Change from baseline to Days 15 and End of Study, up to 55 days
Reported as:
Mean · score on a scale
Change in Insomnia Severity Index (ISI)
score on a scaleLofexidinePlacebo
Day 15-1 ± NA-4 ± 3
EOS-9 ± NA1 ± 1.73
SecondaryChange in Hospital Anxiety and Depression Scale (HADS)

The HADS is a self-reported screening tool for anxiety and depression in nonpsychiatric clinical populations. Responses are based on the relative frequency of symptoms over the preceding week. The scale consists of 14 items, with a subscale of 7 questions for anxiety and 7 questions for depression. Patients rate each item in the subscales on a 4-point scale ranging from 0 (absence) to 3 (extreme presence). Possible scores range from 0 to 21 for each subscale. An analysis of scores on the 2 subscales supported the differentiation of each mood state into 4 ranges: non-cases (scores 0 to 7), mild cases (scores 8 to 10), moderate cases (scores 11 to 15), and severe cases (scores 16 or higher), with lower values being favorable. The subscales are then combined for a total score ranging from 0 to 42. Higher scores indicate greater levels of anxiety or depression. The value reported is the average change from baseline to End of Study.

Time frame:
Change from End of Study to Baseline, up to 55 days
Reported as:
Mean · score on a scale
Change in Hospital Anxiety and Depression Scale (HADS)
score on a scaleLofexidinePlacebo
Change in Hospital Anxiety and Depression Scale (HADS)-2 ± NA-2.3 ± 3.51
SecondaryChange in Average Chronic Pain as Measured by the Numeric Rating Scale (NRS)

A subject selects a whole number (0 to 10) that best indicates the intensity of his/her pain. The format consists of a horizontal line which is anchored by terms defining pain levels where 0 represents no pain and 10 represents worst pain imaginable.

Time frame:
Baseline through Follow-up (assessed daily)
Reported as:
Mean · score on a scale
Change in Average Chronic Pain as Measured by the Numeric Rating Scale (NRS)
score on a scaleLofexidinePlacebo
Day 10 ± NA-0.3 ± 0.82
Day 20 ± NA-1.5 ± 1
Day 30 ± NA-1.4 ± 1.82
Day 4—-0.7 ± 1.53
Day 5-2 ± NA-1.3 ± 1.15
Day 6—-1 ± 1
Day 7-3 ± NA-0.7 ± 1.53
Day 80 ± NA-0.8 ± 2.63
Day 9—-1 ± 0.82
Day 10-1 ± NA-0.5 ± 2.12
Day 11—-0.3 ± 1.15
Day 120 ± NA-1 ± 2.83
Day 13-1 ± NA-1 ± 2
Day 14-1 ± NA-1.3 ± 1.53
Day 15-0.5 ± NA-0.8 ± 1.5
Day 16—-1 ± 0
Day 17—-1 ± 1.41
Day 18—0 ± 1.41
Day 19—-0.5 ± 2.12
Day 20—0 ± 1.41
Day 21—-1.5 ± 2.12
Day 22—-1.2 ± 1.83
Day 23—0 ± 1.41
Day 240 ± NA-0.7 ± 1.53
Day 250 ± NA-0.5 ± 2.12
Day 26—-1 ± 2
Day 270 ± NA0 ± 2.83
Day 28—-0.5 ± 1.73
Day 290 ± NA0.7 ± 1.53
Day 30—-0.7 ± 1.53
Day 310 ± NA-0.7 ± 1.53
Day 320 ± NA-1.5 ± 0.71
Day 33—-2 ± NA
Day 34—-0.5 ± 0.71
Day 35—-1 ± 1
Day 36—-1 ± 1.41
Day 370 ± NA-0.8 ± 0.5
Day 38—-1 ± 1.41
Day 39—-1 ± 1.41
Day 401 ± NA-1.3 ± 2.08
Day 41—-1 ± NA
Day 42—-1 ± 1.41
Day 43-1 ± NA-1 ± 1.41
Day 44—0 ± 1.41
Day 45-1 ± NA-0.5 ± 0.71
Day 46—-0.5 ± 0.71
Day 470 ± NA0 ± 1.41
Day 48-1 ± NA0 ± 1.41
Day 49—-0.5 ± 0.71
Day 50—-0.5 ± 0.71
Day 51-1 ± NA0 ± 1.41
SecondaryChange in Average Overall Pain as Measured by the Numeric Rating Scale (NRS)

The NRS of pain intensity is a unidimensional, segmented numeric version of the visual analog scale. A subject selects a whole number (0 to 10) that best indicates the intensity of his/her pain. The format consists of a horizontal line which is anchored by terms defining pain levels where 0 represents no pain and 10 represents worst pain imaginable.

Time frame:
Day 1 through Day 28 (assessed daily)
Reported as:
Mean · units on a scale
Change in Average Overall Pain as Measured by the Numeric Rating Scale (NRS)
units on a scaleLofexidinePlacebo
Day 10 ± NA0 ± 0
Day 2-2 ± NA-1.3 ± 1.89
Day 30 ± NA-1.4 ± 2.51
Day 4—-0.3 ± 3.21
Day 5-1 ± NA-1 ± 2.65
Day 6—-0.3 ± 3.21
Day 7-2 ± NA-0.7 ± 2.89
Day 8-0.5 ± NA-1.8 ± 3.2
Day 9—-0.5 ± 3
Day 10-2 ± NA-2 ± 2.83
Day 11—-1 ± 2.65
Day 12-2 ± NA-2 ± 2.83
Day 13-13 ± NA-1.3 ± 3.21
Day 14-1 ± NA-1 ± 2.65
Day 15-1 ± NA-2 ± 2.31
Day 16—-0.5 ± 2.38
Day 17—-2 ± 2.83
Day 18—-2 ± 2.83
Day 19—-2 ± 2.83
Day 20—-2 ± 2.83
Day 21—-2 ± 2.83
Day 22—-2 ± 2.28
Day 23—0 ± 1.41
Day 24-2 ± NA-1.7 ± 3.06
Day 25-2 ± NA-2.5 ± 2.12
Day 26—-1.7 ± 3.06
Day 27-2 ± NA-1.5 ± 0.71
Day 281 ± NA-1.5 ± 1.91
SecondaryChange in Worst Chronic Pain as Measured by the Numeric Rating Scale (NRS)

The NRS of pain intensity is a unidimensional, segmented numeric version of the visual analog scale. A subject selects a whole number (0 to 10) that best indicates the intensity of his/her pain. The format consists of a horizontal line which is anchored by terms defining pain levels where 0 represents no pain and 10 represents worst pain imaginable.

Time frame:
Baseline through Day 51 (assessed daily)
Reported as:
Mean · score on a scale
Change in Worst Chronic Pain as Measured by the Numeric Rating Scale (NRS)
score on a scaleLofexidinePlacebo
Day 10 ± NA0 ± 0.63
Day 2-1 ± NA-0.8 ± 0.96
Day 3-1 ± NA0.2 ± 1.3
Day 4—0 ± 1
Day 5-3 ± NA0 ± 1
Day 6—0.7 ± 0.58
Day 7-3 ± NA0.3 ± 0.58
Day 8-0.5 ± NA0.3 ± 0.96
Day 9—0 ± 0
Day 10-1 ± NA0.5 ± 0.71
Day 11—1 ± 1
Day 120 ± NA-0.5 ± 2.12
Day 13-1 ± NA0.3 ± 0.58
Day 14-1 ± NA0 ± 0
Day 15-0.5 ± NA0 ± 0
Day 16—0 ± 0
Day 17—0 ± 0
Day 18—1.5 ± 0.71
Day 19—1.5 ± 0.71
Day 20—0.5 ± 0.71
Day 21—-1 ± 1.41
Day 22—0 ± 0.89
Day 23—0.5 ± 0.71
Day 240 ± NA0.3 ± 0.58
Day 250 ± NA0.5 ± 0.71
Day 26—0 ± 1
Day 27-1 ± NA1.5 ± 0.71
Day 28—0.5 ± 0.58
Day 290 ± NA1.3 ± 0.58
Day 300 ± NA0.3 ± 0.58
Day 310 ± NA0.3 ± 0.58
Day 320 ± NA0.5 ± 0.71
Day 33—1 ± NA
Day 34—1 ± 1.41
Day 35—0 ± 0
Day 36—0 ± 0
Day 37—0.5 ± 1
Day 38—0 ± 0
Day 39—0.5 ± 0.71
Day 401 ± NA0.7 ± 1.15
Day 41—-1 ± NA
Day 42—0 ± 0
Day 43-1 ± NA0 ± 0
Day 44—1.5 ± 0.71
Day 45-2 ± NA1 ± 1.41
Day 46—1 ± 1.41
Day 47-1 ± NA2 ± 1.41
Day 48-1 ± NA1 ± 0
Day 49—0.5 ± 0.71
Day 50—0.5 ± 0.71
Day 51-1 ± NA1 ± 0
SecondaryChange in Worst Overall Pain as Measured by the Numeric Rating Scale (NRS)

The NRS of pain intensity is a unidimensional, segmented numeric version of the visual analog scale. A subject selects a whole number (0 to 10) that best indicates the intensity of his/her pain. The format consists of a horizontal line which is anchored by terms defining pain levels where 0 represents no pain and 10 represents worst pain imaginable.

Time frame:
Day 1 through Day 28 (assessed daily)
Reported as:
Mean · score on a scale
Change in Worst Overall Pain as Measured by the Numeric Rating Scale (NRS)
score on a scaleLofexidinePlacebo
Day 10 ± NA0 ± 0
Day 2-3 ± NA-2.3 ± 1.53
Day 3-2.5 ± NA-1.6 ± 1.82
Day 4—-0.7 ± 2.89
Day 5-3 ± NA-1 ± 1.73
Day 6—0.3 ± 1.15
Day 7-2 ± NA-1 ± 2.65
Day 80.5 ± NA-1.8 ± 2.06
Day 9—-0.8 ± 2.36
Day 10-4 ± NA-3 ± 1.41
Day 11—-1.7 ± 2.52
Day 12-3 ± NA-3 ± 1.41
Day 13-2 ± NA-2 ± 3
Day 14-1 ± NA-1 ± 1.73
Day 15-1.3 ± NA-2.8 ± 0.96
Day 16—-0.8 ± 2.06
Day 17—-3 ± 1.41
Day 18—-2.5 ± 0.71
Day 19—-2.5 ± 0.71
Day 20—-3 ± 1.41
Day 21—-3 ± 1.41
Day 22—-2.7 ± 1.97
Day 23—-1 ± 2.83
Day 24-3 ± NA-2 ± 2.65
Day 25-3 ± NA-2.5 ± 0.71
Day 26—-2 ± 2.65
Day 27-4 ± NA-0.5 ± 3.54
Day 28—-0.5 ± 1.73
SecondaryChange in Daily Opioid Dose Expressed as Morphine Equivalent Dose (MED)
Time frame:
Baseline through Day 28
Reported as:
Median · MME (morphine milligram equivalent)
Change in Daily Opioid Dose Expressed as Morphine Equivalent Dose (MED)
MME (morphine milligram equivalent)LofexidinePlacebo
Day 1-45 ± NA-100 ± NA
Day 2-45 ± NA-30 ± NA
Day 3-45 ± NA-65 ± 49.5
Day 4-45 ± NA-63.3 ± 35.12
Day 5-45 ± NA-66.7 ± 40.41
Day 6—-80 ± 62.45
Day 7-67.5 ± NA-75 ± 25.98
Day 8-67.5 ± NA-60.8 ± 34.13
Day 9—-93.3 ± 50.08
Day 10-67.5 ± NA-45 ± 0
Day 11-67.5 ± NA-78.3 ± 29.3
Day 12-67.5 ± NA-67.5 ± 31.82
Day 13—-78.3 ± 29.3
Day 14—-145 ± NA
Day 16—-155 ± NA
Day 20-67.5 ± NA—
Day 22—-15 ± NA
Day 23—-20 ± NA
Day 24-67.5 ± NA-20 ± NA
Day 25-67.5 ± NA—
Day 27-67.5 ± NA—
Day 28—-20 ± NA
SecondaryChange in Daily Opioid Dose as a Percentage of the Baseline MED
Time frame:
Baseline through Day 28
Reported as:
Mean · MME (morphine milligram equivalent)
Change in Daily Opioid Dose as a Percentage of the Baseline MED
MME (morphine milligram equivalent)LofexidinePlacebo
Day 1-50 ± NA-50 ± NA
Day 2-50 ± NA-50 ± NA
Day 3-50 ± NA-50 ± 0
Day 4-50 ± NA-50 ± 0
Day 5-50 ± NA-51.7 ± 2.89
Day 6—-58.3 ± 14.43
Day 7-75 ± NA-65 ± 17.32
Day 8-75 ± NA-52.1 ± 21.95
Day 9—-74.2 ± 1.44
Day 10-75 ± NA-56.3 ± 26.52
Day 11-75 ± NA-66.7 ± 14.43
Day 12-75 ± NA-75 ± 0
Day 13—-66.7 ± 14.43
Day 14—-72.5 ± NA
Day 16—-77.5 ± NA
Day 20-75 ± NA—
Day 22—-7.5 ± NA
Day 23—-10 ± NA
Day 24-75 ± NA-10 ± NA
Day 25-75 ± NA—
Day 27-50 ± NA—
Day 28—-10 ± NA

Adverse events

Collected over Day 1 of drug administration through 30 day follow up, up to 57 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lofexidine0/1 (0%)0/1 (0%)0/1 (0%)
Placebo0/3 (0%)0/3 (0%)3/3 (100%)
Most frequent other events
Most frequent other events
EventLofexidinePlacebo
DiarrhoeaGastrointestinal disorders0/11/3
SneezingRespiratory, thoracic and mediastinal disorders0/11/3
RashSkin and subcutaneous tissue disorders0/11/3
YawningRespiratory, thoracic and mediastinal disorders0/11/3
LethargyNervous system disorders0/11/3

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)LofexidinePlaceboTotal
<=18 years000
Between 18 and 65 years134
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)LofexidinePlaceboTotal
Female011
Male123
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)LofexidinePlaceboTotal
Hispanic or Latino101
Not Hispanic or Latino033
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)LofexidinePlaceboTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White134
More than one race000
Unknown or Not Reported000
08

Study locations

12 sites
  • Westview Clinical Research, LLC
    Placentia, California 92870, United States
  • Vitamed Research
    Rancho Mirage, California 92270, United States
  • Gold Coast Research, LLC
    Plantation, Florida 33317, United States
  • Georgia Clinical Research, LLC
    Lawrenceville, Georgia 30044, United States
  • Injury Care Research
    Boise, Idaho 83713, United States
  • Global Scientific Innovations
    Evansville, Indiana 47714, United States
  • Integrated Clinical Trial Services, Inc.
    West Des Moines, Iowa 50265, United States
  • Neuroscience Research Center, LLC
    Overland Park, Kansas 66210, United States
  • Otrimed Corporation (Otrimed Clinical Research Center)
    Edgewood, Kentucky 41017, United States
  • University of Rochester
    Rochester, New York 14624, United States
  • Duke Innovation Pain Therapies Clinic at Brier Creek
    Raleigh, North Carolina 27617, United States
  • The Center for Clinical Research, LLC
    Winston-Salem, North Carolina 27103, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2019 to primary completion in Nov 2019, 3 months.

Results were first posted in Oct 2024, 4 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2019
First posted
Aug 28, 2019
StartActual
Aug 2, 2019
Primary completionActual
Nov 27, 2019
CompletionActual
Nov 27, 2019
Results first posted
Oct 21, 2024
Last update
Oct 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04070157
Lead sponsor
USWM, LLC (dba US WorldMeds)
Responsible party
Sponsor
First posted
Aug 28, 2019
Start date
Aug 2, 2019
Primary completion
Nov 27, 2019
Completion
Nov 27, 2019
Results posted
Oct 21, 2024
Last update
Oct 21, 2024

Study contacts

John Peppin, DO
study director · US WorldMeds Contract Medical Monitor

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lofexidine

Start the discussion